MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm® Therapy

  • Patient treated at the University of Giessen and Charité University Medical Center Berlin in an interdisciplinary cooperation
  • The first treatment approvals have been received from German state insurance companies

Berlin, October 10, 2011 - MagForce AG (FSE:MF6), a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company’s NanoTherm® therapy. The first part of the therapy (instillation of the nanoparticles) was carried out at the University Giessen and subsequent steps (nanoparticle activation and the accompanying radiotherapy) were performed at the Charité University Medical Center Berlin. Based on an individual patient agreement, the treatment costs are being covered by a German state insurance company.


 “We are pleased that treatment with NanoTherm therapy for brain tumors patients has begun, and especially that treatment costs have been supported by a number of state insurance companies through individual patient agreements.  This is a great milestone for both our novel technology and for MagForce as a company,” said Dr. Peter Heinrich, CEO of MagForce. “Through our collaborations with experts in both Germany and internationally, we plan to further develop this treatment approach for a variety of solid tumor indications with high medical need.”


Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults.  Recurrent glioblastoma is the reoccurring growth following treatment of the primary tumor.



MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivatorTM are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries.



NanoTherm® therapy involves the direct injection of magnetic nanoparticles into the tumor and their subsequent heating by an alternating magnetic field. The water-soluble nanoparticles are approximately 15 nanometers in diameter and contain an iron oxide core with an aminosaline coating, which causes the particles to agglomerate following injection. The particles are then activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced within the tumor. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.